1. Doboszewska, Urszula, Sawicki, Jan, Sajnóg, Adam, Sowa, Ireneusz, Wlaź, Piotr. 2022. Alterations of Serum Magnesium Concentration in Animal Models of Seizures and Epilepsy-The Effects of Treatment with a GPR39 Agonist and Knockout of the Gpr39 Gene. In Cells, 11, . doi:10.3390/cells11131987. https://pubmed.ncbi.nlm.nih.gov/35805072/
2. Rychlik, Michal, Starowicz, Gabriela, Starnowska-Sokol, Joanna, Mlyniec, Katarzyna. 2022. The Zinc-sensing Receptor (GPR39) Modulates Declarative Memory and Age-related Hippocampal Gene Expression in Male Mice. In Neuroscience, 503, 1-16. doi:10.1016/j.neuroscience.2022.09.002. https://pubmed.ncbi.nlm.nih.gov/36087899/
3. Hua, Dongxu, Huang, Wanlin, Xie, Qiyang, Li, Peng, Sheng, Yanhui. 2024. Targeting GPR39 in structure-based drug discovery reduces Ang II-induced hypertension. In Communications biology, 7, 1441. doi:10.1038/s42003-024-07132-2. https://pubmed.ncbi.nlm.nih.gov/39500998/
4. Grunddal, Kaare V, Diep, Thi A, Petersen, Natalia, Cox, Helen, Holst, Birgitte. 2021. Selective release of gastrointestinal hormones induced by an orally active GPR39 agonist. In Molecular metabolism, 49, 101207. doi:10.1016/j.molmet.2021.101207. https://pubmed.ncbi.nlm.nih.gov/33711555/
5. Alén, Begoña O, Leal-López, Saúl, Alén, María Otero, Camiña, Jesús P, Pazos, Yolanda. . The role of the obestatin/GPR39 system in human gastric adenocarcinomas. In Oncotarget, 7, 5957-71. doi:10.18632/oncotarget.6718. https://pubmed.ncbi.nlm.nih.gov/26716511/